**International Publication Number**

WO 2011/131661 A1

---

| C07C 57/58 (2006.01) | (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). |
| A61P 25/28 (2006.01) | Published: with international search report (Art. 21(3)) |
| A61K 31/19 (2006.01) | before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(b)). |
| A61P 43/00 (2006.01) |

---

| International Application Number: | (21) International Application Number: PCT/EP2011/056224 |
| English |
| (25) Filing Language: | (26) Publication Language: English |
| (72) Inventors; and |
| (74) Agent: MINOJA, Fabrizio; Bianchetti Bracco Minoja S.r.l., Via Plinio, 63, I-20129 Milano (IT). |

---

(54) **Title:** 1-(2-FLUOROBIPHENYL-4-YL)-ALKYL CARBOXYLIC ACID DERIVATIVES FOR THE THERAPY OF TRANSTHYRETIN AMYLOIDOSIS

(57) **Abstract:** The invention relates to the use of derivatives of 1-(2-fluorobiphenyl-4-yl)-alkyl carboxylic acid as agents capable of stabilising the tetrameric native state of transthyretin for the prophylaxis and treatment of amyloidosis.
1-(2-FLUOROBIPHENYL-4-YL)-ALKYL CARBOXYLIC ACID DERIVATIVES FOR THE THERAPY OF TRANSTHYRETIN AMYLOIDOSIS

TECHNICAL FIELD

The present invention relates to the therapy of amyloidosis. More particularly, the invention relates to the use of 1-(2-fluorobiphenyl-4-yl)-alkyl carboxylic acid derivatives as agents capable of stabilizing the tetrameric native state of transthyretin for the prophylaxis and treatment of amyloidosis.

BACKGROUND OF THE INVENTION

Amyloidosis is a serious disease caused by extracellular deposition of insoluble abnormal fibrils. Systemic amyloidosis, with deposits in the viscera, blood vessels and connective tissue, is usually fatal, causing about one per thousand deaths in developed countries.

Amyloid is deposited when there is: (i) sustained exposure to either normal or increased concentrations of a normal, potentially amyloidogenic, protein; (ii) when an abnormal amyloidogenic protein is produced as a consequence of an acquired disease; or (iii) when a gene mutation encodes an amyloidogenic variant protein. Fibrillogenesis results from reduced stability of the native fold of the fibril precursor protein, so that under physiological conditions it populates partly unfolded intermediate states which aggregate as stable amyloid fibrils.

Wild type-transthyretin (WT-TTR) is the normal plasma protein, synthesized by hepatocytes and by the choroid plexus, which transports thyroid hormone and retinol binding protein.

TTR is inherently amyloidogenic and forms microscopic amyloid deposits of uncertain clinical significance in all individuals aged over 80 years. Massive deposits in the heart can also occur, causing fatal senile
systemic amyloidosis (SSA). The inherent amyloidogenicity of wild type transthyretin is markedly enhanced by most of the reported >80 different point mutations which encode single residue substitutions in the transthyretin sequence. These mutations cause autosomal dominant adult onset hereditary amyloidosis, a universally fatal condition affecting about 10,000 patients worldwide. Said diseases are mainly grouped into two broad groups: familial amyloid polyneuropathy (FAP) and familial amyloid cardiomyopathy (FAC).

Amyloidogenic mutations occur in all ethnic groups, but by far the most common, V30M, clusters in three geographical foci: Northern Portugal, Northern Sweden and parts of Japan. Other common amyloidogenic variants are T60A, L58H, L55P, I84S and V112I. Among the pathogenic variants of TTR so far identified, the V122I variant is of particular importance as is carried by 3-4% of African Americans: 1.3 million people, including 13,000 individuals homozygous for the mutation. It is the second most common pathogenic mutation in that population after sickle cell haemoglobin.

The variant V122I is particularly associated to cardiac transthyretin amyloidosis which presents as progressive, ultimately fatal, heart failure due to restrictive cardiomyopathy. Said pathology is rarely suspected and is usually misdiagnosed as coronary heart disease.

So far there is only a treatment available for FAP, i.e. gene therapy mediated by surgical replacement of the patient's liver, the organ secreting TTR subject to misfolding into the blood stream. The disadvantages of this approach include its invasiveness for the donor and recipient, the requirement for life-long immune suppression, and the limited effectiveness for some mutations for reasons that are not yet clear. Currently there is no effective treatment either for SSA associated with WT-TTR deposition or for FAC.

Therefore, a small molecule therapeutic strategy for all TTR-based amyloid diseases would be highly advantageous.
The most common approach to the potential treatment of transthyretin amyloidosis has been to identify small molecule ligands able to stabilise the native TTR tetrameric structure and thereby to prevent the dissociation of TTR into monomers which are in turn prone to misassembly leading to fibrillogenic aggregation.

Ideally, good fibrillogenesis inhibitors should bind with high affinity, dissociate slowly, and exhibit high binding selectivity to TTR in the blood.

For example, several non-steroidal anti-inflammatory drugs (NSAIDS) such as diclofenac, flufenamic acid, diclofenac, flurbiprofen and diflunisal have been shown to act as stabilisers of the tetrameric structure of TTR, inhibiting the formation of TTR amyloid fibrils in vitro. However, because said drugs are cyclooxygenase-2 inhibitors, their long-term administration could lead to gastrointestinal side effects.

Polyphenols such as trans-resveratrol are known to bind specifically to thyroxine binding sites of TTR (Klabunde et al., Nat. Struct Biol 2000, 7, 312). However said kind of drugs are also known to be very aspecific, they might have low bioavailability, and may be endowed with several ancillary effects.


In view of the above considerations, there is still the need for more effective products with an established safety profile in humans that binds to TTR and hence can be useful for treating TTR amyloidosis.

WO 2004/074232 and WO 2004/073705 disclose therapeutic agents for neurodegenerative diseases such as Alzheimer’s disease.

It has now been found that certain halogen derivatives therein described can effectively be used for preventing and/or treating TTR amyloidosis.

**SUMMARY OF THE INVENTION**

According to the first aspect, the present invention is directed to
compounds of general formula (I)

wherein

$R_1$ is hydrogen or linear or branched $C_1$-$C_4$ alkyl, preferably methyl;

$R_2$ is linear or branched $C_1$-$C_4$ alkyl, preferably methyl,

or $R_1$ and $R_2$ taken together with the carbon atom they are linked to, form a 3 to 6 carbon atoms ring, preferably cyclopropyl; and

$R_3$ represents one or more groups, which are the same or different from each other, independently selected from halogen atoms, preferably chlorine;

for use in the prevention and/or treatment of transthyretin (TTR) amyloidosis diseases.

In a second aspect, the present invention is directed to the use of the compounds of general formula (I) in the manufacture of a medicament for the prevention and/or treatment of transthyretin (TTR) amyloidosis diseases.

In another aspect, the present invention is also directed to the above uses of polymorphs, pharmaceutically acceptable salts and pro-drugs of the compounds of general formula (I).

In a further aspect, the invention provides a method for preventing and/or treating systemic amyloidosis in a patient, comprising administering to said patient an effective amount of a compound of general formula (I), including polymorphs, pharmaceutically acceptable salts and pro-drugs thereof.
DEFINITIONS

Unless otherwise provided in the present description, within the compounds of general formula (I), the phenyl ring bears one or more halogen atoms therein referred to as R₃ groups.

From the above, it is clear to the skilled person that any of the said halogen atoms, which can be the same or different from each other, may be thus present in any possible free position of the phenyl ring itself.

The term “halogen atoms” includes fluorine, chlorine, bromine, and iodine.

The expression “linear or branched C₁-C₄ alkyl” refers to straight-chained and branched-chained alkyl groups wherein the number of constituent carbon atoms is in the range 1 to 4. Exemplary alkyl groups are methyl, ethyl, n-propyl, isopropyl and tert-butyl.

The expression “3 to 6 carbon atoms ring” refers to cyclic non-aromatic hydrocarbon groups containing from 3 to 6 carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

The term “polymorphs” refers to a different crystal structure of the same solid substance. They exhibit different melting points, solubilities (which affect the dissolution rate of the drug and consequently its bioavailability in the body), X-ray crystal and diffraction patterns.

The expression “substantially pure polymorph” refers to a sample in which the polymorph is present in a substantial excess over other polymorphs of the same compound, i.e. in an amount exceeding 75%, more preferably exceeding 90%, even more preferably exceeding 95%, and most preferably exceeding 99% by weight of the total weight of the compound in the sample.

The term “prodrug” refers to a substance administered in an inactive form that is then metabolized in the body in vivo into the active compound with the aim of optimizing absorption, distribution, metabolism, and
excretion.

The term "TTR amyloidosis" refers to a form of amyloidosis disease due to the misfolding of the transthyretin protein.

The term "prophylaxis" refers to the use for reducing the occurrence of the disease, while the term "treatment" refers to the use for palliative, curing, symptom-allievating, symptom-reducing, disease regression-inducing therapy.

**DETAILED DESCRIPTION OF THE INVENTION**

Transthyretin (TTR) is a 55 kDa homotetramer characterized by 2,2,2 symmetry, having two identical funnel-shaped binding sites at the dimer-dimer interface, where the thyroid hormone L-thyroxine (T4) can be bound in blood plasma and cerebrospinal fluid.

Besides taking part to the transport of T4, TTR forms a macromolecular complex with the retinol binding protein, thereby participating also in the transport of retinol. The binding sites of thyroxine and retinol-binding protein are present in distinct regions of TTR, such that there is no interdependence of the binding of the hormone and of retinol-binding protein.

TTR misfolding including tetramer dissociation render the protein capable of misassembly, ultimately affording amyloid aggregates.

Misfolding of transthyretin (TTR), including tetramer dissociation into monomers followed by tertiary structural changes within the monomer, is sufficient for TTR misassembly into amyloid and other abnormal quaternary structures associated with three TTR amyloidosis diseases: senile systemic amyloidosis (SSA), familial amyloid polyneuropathy (FAP), and familial amyloid cardiomyopathy (FAC).

The invention is thus directed to the compounds of general formula (I)
wherein R₁, R₂ and R₃ have the above reported meanings, including polymorphs, pharmaceutically acceptable salts and pro-drugs thereof, for use in the prevention and/or treatment of transthyretin (TTR) amyloidosis diseases.

Likewise, the invention also relates to the use of the above compounds and derivatives thereof, in the manufacture of a medicament for the prophylaxis and/or treatment of TTR amyloidosis diseases.

The invention is based, at least in part, on the discovery that compounds of formula (I) have the effect of stabilizing the TTR tetramer and are hence excellent inhibitors of TTR tetramer dissociation and TTR amyloidogenesis.

In particular, some representative members of said class of compounds have a higher binding affinity to TTR as compared to trans-resveratrol, whereas the latter compound exhibits a higher binding affinity as compared to diflunisal and 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid, also known as tafamidis, the most representative compound of WO 2009/040405.

This may in turn provide for a better stabilisation of the non-amyloidogenic tetrameric form of TTR.

A first group of preferred compounds of general formula (I) is that wherein the phenyl ring bearing one or more substituents R₃ is substituted in 3’ and 5’ positions with two chlorine atoms, according to the general formula (II) below
5 wherein \( R_1 \) and \( R_2 \) are as defined above.

In preferred embodiments, \( R_1 \) is H and \( R_2 \) is methyl or, alternatively, both \( R_1 \) and \( R_2 \) are methyl.

In another preferred embodiment, \( R_1 \) and \( R_2 \) form with the carbon atom they are linked a cyclopropyl group.

Preferred compounds of formula (II) are the following:

2-(3',5'-dichloro-2-fluoro-biphenyl-4-yl) propionic acid;

2-methyl-(3',5'-dichloro-2-fluoro-biphenyl-4-yl) propionic acid (herein referred to with the experimental code CHF 4795); and

(3',5'-dichloro-2-fluorobiphenyl-4-yl)cyclopropane carboxylic acid.

A second group of preferred compounds of formula (I) is that wherein the phenyl ring bearing one or more \( R_3 \) substituents is substituted in 3' and 4' positions with two chlorine atoms, according to the general formula (III)
both $R_1$ and $R_2$ are methyl.

In another preferred embodiment, $R_1$ and $R_2$ form a cyclopropyl group.

Preferred compounds of formula (III) are the following:

- 2-($3',4'$-dichloro-2-fluoro-biphenyl-4-yl) propionic acid;
- 2-methyl-($3',4'$-dichloro-2-fluoro-biphenyl-4-yl) propionic acid; and
- 1-($3',4'$-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid (herein also referred to with the experimental code CHF 5074).

CHF 5074 is a particularly preferred compound.

The compounds of general formula (I) may advantageously be used in any form, either amorphous or crystalline, including solvates or hydrates thereof. Preferably, they are used in crystalline form.

For example, as disclosed in the co-pending application EP 10158954.7, the entire content of which is incorporated herein by reference, CHF 5074 can exist in three stable crystalline polymorphic forms. Accordingly, the invention includes the use of any of said polymorphs, either in substantially pure form or admixed in any proportion.

In view of the close relationship between the compounds of formula (I) in free acid form and those in the form of salts, the present invention is also directed to the use of pharmaceutically acceptable salts thereof.

Pharmaceutically acceptable salts according to the invention thus include those formed with both common organic and inorganic bases.

For example, the salts disclosed in the co-pending patent application EP 10158954.7, may advantageously be utilized.

The compounds of general formula (I) may also be administered in form of prodrugs. Suitable prodrugs may be esters with common alcohols for pharmaceutical use such as ethanol or polyalcohols such as sorbitol, with sugars such as glucose, or with sugar acids such as ascorbic acid. Other suitable prodrugs may be those disclosed in the patent application
The compounds of general formula (I) may be combined with one or more pharmaceutically acceptable carriers or excipients to provide suitable pharmaceutical compositions.

The pharmaceutically acceptable carriers or excipients may be advantageously selected from the group consisting of, diluents, wetting agents, emulsifying agents, binders, coatings, fillers, glidants, lubricants, disintegrants, preservatives, stabilizers, surfactants, pH buffering substances, flavouring agents and the like. Comprehensive guidance on pharmaceutical excipients is given in Remington’s Pharmaceutical Sciences Handbook, XVII Ed. Mack Pub., N.Y., U.S.A.

The pharmaceutical compositions of the invention may be formulated for administration by any convenient route, e.g. by oral, parenteral, topical, inhalation, buccal, nasal, rectal, vaginal, transdermal administration. Suitable dosage forms can include tablets, capsules, lozenges, suppositories, solutions, emulsions, suspensions, syrups, ointments, creams, oils, and powders. Preferably, the pharmaceutical compositions of the invention will be administered orally using appropriate dosage forms, such as capsules, tablets, caplets etc.

The dosage of the compounds of general formula (I) and of their salts and prodrugs can vary within wide limits depending on the nature of the disease to be treated, the type of patient, and the mode of administration. A person skilled in the art can determine a therapeutically effective amount for each patient and thereby define the appropriate dosage. For example, when the compound quoted with the code CHF 5074 is administered by oral route to humans, a typical daily dosage might fall within the range of 5 to 2000 mg, preferably between 100 mg and 1000 mg, administered in a single or multiple daily dosage units. Thus, a single dose of the pharmaceutical preparations of
the invention conveniently comprises between about 100 and 1000 mg of CHF 5074 or salt thereof.

The compounds of the present invention may be of use in the treatment or prophylaxis of any wild type TTR amyloidosis disease. They may be also of use for delaying the onset or slowing the progression of said diseases.

In a preferred mode, the wild-type TTR amyloidosis disease is senile systemic amyloidosis, or familial amyloidosis polyneuropathy.

More particularly, the familial amyloidosis polyneuropathy (FAP) is characterized by V30M mutation.

In another preferred mode, the transthyretin amyloidosis disease is familial amyloidosis cardiomyopathy (FAC). More particularly, the familial amyloidosis cardiomyopathy is characterized by a V122I mutation.

The following Examples illustrate in detail the invention.

EXAMPLES

**Example 1 - Analysis of the interaction with wild-type human transthyretin (TTR), by using fluorometric techniques**

The aim of this study is to investigate whether representative compounds of the invention are able to stabilize the oligomeric native state of TTR through the interaction with the thyroxine binding sites in comparison to reference compounds.

Recombinant human wild-type TTR and some of its major amyloidogenic genetic variants were produced using *E. coli* as expression organism as reported in Zanotti et al., FEBS J. 2008, 275, 5841).

To compare binding properties of the compounds CHF 5074 and CHF 4795 with those of trans-resveratrol, diflunisal and tafamidis, the interactions of such compounds with wild-type TTR were analyzed.

The analysis of interactions was based on fluorescence measurements.

It is known that the fluorescence emission of the two fluorescent probes
8-aniilino-1-naphthalene sulfonate (ANS) and trans-resveratrol increases substantially when these compounds are specifically bound within thyroxine binding sites in TTR (Smith et al., Biochim Biophys Acta 1994, 1199, 76, and Reixach et al., J. Biol. Chem. 2008, 283:2098, respectively).

While ANS possesses a relatively low binding affinity for TTR, trans-resveratrol has a high binding affinity, greater than that of thyroxine.

In competitive binding experiments, using the fluorescence signals provided by the two fluorescent probes, or by those of the comparative compounds, we were able to assess the relative affinity of CHF 5074, CHF 4795, trans-resveratrol, diflunisal and tafamidis for human TTR.

All data were obtained at 20°C in the presence of 50 mM Na phosphate buffer, pH 7.2, 150 mM NaCl.

The results were the following:

The fluorescence emission (excitation at 320 nm) of unbound trans-resveratrol (10 µM) was quite low and increased substantially upon binding to TTR (5 µM). The emission peak of TTR-bound trans-resveratrol (maximum at approx. 390 nm) was nearly completely abolished in the presence of 10 µM CHF 5074 or CHF 4795, consistent with a higher binding affinity of said compounds relative to that of trans-resveratrol.

The fluorescence emission (excitation at 360 nm) of unbound ANS (10 µM) was quite low and increased substantially upon binding to TTR (5 µM).

The emission peak of TTR-bound ANS was nearly completely abolished in the presence of 10 µM CHF 5074 or CHF 4795, consistent with a higher binding affinity of said compounds relative to that of ANS.

The fluorescence emission (excitation at 320 nm) of unbound tafamidis (10 µM) was characterized by a maximum at approx. 375 nm, whereas in the presence of 10 µM TTR its emission was significantly enhanced and was red
shifted by approx. 40 nm. The emission peak of TTR-bound tafamidis (10 \( \mu \text{M} \)) was nearly completely shifted to that of unbound tafamidis in the presence of 10 \( \mu \text{M} \) CHF 5074 or CHF 4795, consistent with a higher binding affinity of CHF 5074 and CHF 4795 relative to that of tafamidis. The fluorescence emission of 10 \( \mu \text{M} \) TTR-bound tafamidis (maximum at approx. 415 nm) was nearly completely shifted to that of TTR-bound trans-resveratrol and unbound tafamidis (maximum at approx. 380 nm) upon incubation of TTR-bound tafamidis with 10 \( \mu \text{M} \) resveratrol, consistent with a higher binding affinity of trans-resveratrol relative to that of tafamidis.

The fluorescence emission upon excitation at 320 nm of bound and unbound diflunisal (10 \( \mu \text{M} \)) was characterized by similar intensities and maxima (at approx. 420 nm); the intensity of fluorescence emission of TTR-bound diflunisal was drastically reduced upon excitation at 340 nm. Under the latter excitation condition, when TTR-bound diflunisal (10 \( \mu \text{M} \)) was exposed to equimolar trans-resveratrol, a spectrum similar to that of TTR-bound trans-resveratrol rather than to that of TTR-bound diflunisal was obtained, consistent with a higher binding affinity of trans-resveratrol relative to that of diflunisal.

Taken together, the data of competitive binding assays have shown that CHF 5074 and CHF 4795 have a higher binding affinity to TTR as compared to trans-resveratrol, whereas the latter compound exhibits a higher binding affinity as compared to tafamidis and diflunisal.

The quite high affinity exhibited by CHF 5074 and CHF 4795 appears to be very advantageous for two reasons: i) since TTR stabilization is due to the binding of ligands inside the thyroxine binding sites, a larger stabilizing effect is expected for ligands with the highest affinity, at least at the neutral pH (close to that of blood plasma) used in competitive binding experiments; ii) a higher binding selectivity for TTR is expected for high affinity ligands in
blood plasma, where other binding proteins, especially serum albumin, might compete with TTR for the binding of inhibitors of TTR fibrillogenesis.

**Example 2 - Evaluation of the inhibitory effect on in vitro fibrillogenesis by human wild-type TTR and two major amyloidogenic variants (V30M and V122I)**

The aim of this study was to evaluate the inhibitory effect of the same representative compounds of the inventions tested in Example 1 in vitro fibrillogenesis by human wild-type TTR and two major amyloidogenic variants (V30M and V122I) at moderately acidic pH, in comparison to reference compounds.

To highlight the inhibitory effect of CHF 5074 and CHF4795 versus diflunisal and tafamidis on in vitro fibrillogenesis by wild-type, V30M and V122I TTR at moderately acid pH, we followed the kinetics of fibril formation by these proteins, by monitoring the increase in turbidity at 400 nm as reported in Johnson et al., 2008, J Med Chem. 51:260, upon incubation with TTR.

The final concentration of TTR was of 3.6 µM, which is close to its physiological plasma concentration, with fibrillogenesis inhibitors at a final concentration of 10.8 µM.

According to the procedure adopted for other inhibitors of fibrillogenesis (Johnson et al., 2008, J Med Chem. 51:260), TTR was incubated with each inhibitor at neutral pH (10 mM Na phosphate buffer, pH 7.2, 100 mM KCl, 1 mM EDTA) for 30 min at ambient temperature, prior to the incubation of the protein at acidic pH (200 mM Na Acetate buffer, pH 4.4, 100 mM KCl, 1 mM EDTA) at 37°C in order to promote fibrillogenesis.

Inhibitory effect data represent the average of two independent measurements for each compound.
The results are the following.

The kinetics of wild-type TTR fibrillogenesis is nearly complete within 100 hours upon incubation at acidic pH. CHF 5074, CHF 4795 and the reference compounds diflunisal and tafamidis exhibited quite similar inhibitory effects (about 75% inhibition) on fibrillogenesis.

The kinetics of V30M TTR fibrillogenesis was similar to that obtained with wild-type TTR. CHF 5074, CHF 4795 and the reference compounds diflunisal and tafamidis exhibited inhibitory effects similar to those observed with wild-type TTR.

The kinetics of V122I TTR fibrillogenesis appeared to be remarkably faster as compared to wild-type TTR in the same conditions, and at the same time CHF 5074, CHF 4795 and the reference compounds diflunisal and tafamidis exhibited more pronounced inhibitory effects (about 92% inhibition) on fibrillogenesis.

Taken together, the data demonstrate a remarkable inhibitory effect on TTR fibrillogenesis for CHF 5074 and CHF 4795, similar to that of reference compounds that are currently studied for therapeutic use in TTR amyloidoses.
CLAIMS

1. A compound of general formula (I)

wherein
R₁ is hydrogen or linear or branched C₁-C₄ alkyl;
R₂ is linear or branched C₁-C₄ alkyl;
or R₁ and R₂ taken together with the carbon atom they are linked to, form a 3 to 6 carbon atoms ring; and
R₃ represents one or more groups independently selected from halogen atoms;
or a polymorph, pharmaceutically acceptable salt, or prodrug thereof for use in the prevention and/or treatment of transthyretin (TTR) amyloidosis diseases.

2. The compound according to claim 1, wherein the disease is selected from the group of senile systemic amyloidosis, familial amyloidosis polyneuropathy, and familial amyloidosis cardiomyopathy.

3. The compound according to claim 2, wherein the familial amyloidosis polyneuropathy is characterized by V30M mutation.

4. The compound according to claim 2, wherein the familial amyloidosis cardiomyopathy is characterized by a V122I mutation.

5. The compound according to any one of claims 1 to 4, wherein R₃ is
6. The compound according to claim 5, having the formula (II)

![Chemical Structure](image)

(II)

7. The compound according to claim 6, wherein $R_1$ is H and $R_2$ is methyl

8. The compound according to claim 6, wherein both $R_1$ and $R_2$ are methyl.

9. The compound according to claim 6, wherein $R_1$ and $R_2$ form with the carbon they are linked to a cyclopropyl group.

10. The compound according to claim 6 selected from the group consisting of

   - 2-(3',5'-dichloro-2-fluoro-biphenyl-4-yl) propionic acid;
   - 2-methyl-(3',5'-dichloro-2-fluoro-biphenyl-4-yl) propionic acid (CHF 4795); and
   - (3',5'-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid.

11. The compound according to claim 5, having the formula (III)

![Chemical Structure](image)

(III)

12. The compound according to claim 11, wherein $R_1$ is H and $R_2$ is methyl

13. The compound according to claim 11, wherein both $R_1$ and $R_2$ are
methyl.

14. The compound according to claim 11, wherein R₁ and R₂ form with the carbon they are linked to a cyclopropyl group.

15. The compound according to claim 11 selected from the group consisting of

2-(3’,4’-dichloro-2-fluoro-biphenyl-4-yl) propionic acid;
2-methyl-(3’,4’-dichloro-2-fluoro-biphenyl-4-yl) propionic acid; and
1-(3’,4’-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid (CHF 5074).

16. The compound according to claim 15, which is 1-(3’,4’-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07C57/58 A61K31/19 A61P25/28 A61P43/00
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>EP 2 133 322 A1 (CHIESI FARMA SPA [IT]) 16 December 2009 (2009-12-16) paragraph [0093]</td>
<td>1-5,11, 14-16</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C. See patent family annex.

Date of the actual completion of the international search 26 August 2011

Date of mailing of the international search report 02/09/2011

Name and mailing address of the ISA/
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV RIJSWIJK
Tel: (+31-70) 340-3040,
Fax: (+31-70) 340-3016

Authorized officer Delanghe, Patrick
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WO 2006/020850 A2 (MYRIAD GENETICS INC [US]; HOBDEN ADRIAN [US]) 23 February 2006 (2006-02-23) claim 27</td>
<td>1-6, 9-11, 14-16</td>
</tr>
<tr>
<td>Patent document cited in search report</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>-----------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>EP 2133322</td>
<td>16-12-2009</td>
<td>AU 2009256959 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2723878 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 102046576 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 2285765 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2009149797 A1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KR 20110010633 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2009312426 A1</td>
</tr>
<tr>
<td>WO 2006020850</td>
<td>23-02-2006</td>
<td>NONE</td>
</tr>
</tbody>
</table>